GRI Bio (NASDAQ: GRI) Bolsters Patent Portfolio
June 27, 2023 08:45 ET
|
GRI Bio, Inc.
- U.S. patent issuance for lead program, GRI-0621, in development for the treatment of idiopathic pulmonary fibrosis (IPF) - Company building a robust global patent estate LA JOLLA, CA, June...
GRI Bio (NASDAQ: GRI) to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest
June 15, 2023 08:45 ET
|
GRI Bio, Inc.
- Live webcast fireside chat on Thursday, June 22nd at 12:00 PM ET LA JOLLA, CA, June 15, 2023 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company...
GRI Bio (NASDAQ: GRI) Announces Corporate Rebranding and Launch of New Website
June 13, 2023 08:35 ET
|
GRI Bio, Inc.
Company reiterates commitment to providing much-needed treatment options for inflammatory, fibrotic and autoimmune diseases LA JOLLA, CA, June 13, 2023 (GLOBE NEWSWIRE) -- GRI Bio, Inc....
GRI Bio (NASDAQ: GRI) Provides Business Outlook and Highlights Upcoming Milestones for Innovative Pipeline of NKT Cell Modulators
May 22, 2023 08:45 ET
|
GRI Bio, Inc.
Rapidly advancing clinical pipeline in potential high-value inflammatory, fibrotic and autoimmune diseases Leading NKT regulation technology targeting earlier in the inflammatory cascade to...
GRI Bio (NASDAQ: GRI) to Present at the Virtual Investor New to the Street Event
April 27, 2023 09:05 ET
|
GRI Bio, Inc.
- Live moderated webcast with members of the GRI Bio management team on Wednesday, May 3rd at 2:00 PM ET LA JOLLA, CA, April 27, 2023 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or...
GRI Bio (NASDAQ: GRI) Announces Appointment of Leanne Kelly as Chief Financial Officer
April 25, 2023 08:45 ET
|
GRI Bio, Inc.
- Financial executive bringing over 20 years of experience in accounting, finance and management with a foundation established from big four accounting firm LA JOLLA, CA, April 25, 2023 (GLOBE...
GRI Bio (NASDAQ: GRI) Announces Board of Director Appointments Adding Leadership and Expertise Spanning a Combined 75 Years in Both Public and Private Sectors in the Life Sciences Industry
April 24, 2023 08:05 ET
|
GRI Bio, Inc.
LA JOLLA, CA, April 24, 2023 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell...
Vallon Pharmaceuticals Completes Merger with GRI Bio, Inc.
April 21, 2023 11:55 ET
|
Vallon Pharmaceuticals Inc.
Combined company will operate as GRI Bio, Inc. and advance innovative pipeline of Natural Killer T (“NKT”) modulating therapies for the treatment of inflammatory, fibrotic and autoimmune...
Vallon Pharmaceuticals Announces Stockholder Approval of Merger with GRI Bio, Inc. and Reverse Stock Split
April 20, 2023 18:45 ET
|
Vallon Pharmaceuticals Inc.
Vallon’s board approves 1-for-30 reverse stock split Merger expected to close April 21, 2023 PHILADELPHIA, PA, April 20, 2023 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals, Inc. (NASDAQ: VLON)...
Vallon Pharmaceuticals Adjourns Special Meeting of Stockholders Until April 20, 2023
April 12, 2023 16:05 ET
|
Vallon Pharmaceuticals Inc.
Board of Directors unanimously recommend Vallon stockholders to vote “FOR” all proposals outlined in the Company’s definitive Proxy Statement (the “Proxy”) in order to close the proposed merger with...